Department of Health Sciences, University of Genoa, Via Pastore 1, 16132, Italy; Hospital Hygiene Unit, Galliera Hospital, Mura delle Cappuccine 14, 16128 Genoa, Italy.
Department of Health Sciences, University of Genoa, Via Pastore 1, 16132, Italy.
J Infect Public Health. 2018 Mar-Apr;11(2):171-177. doi: 10.1016/j.jiph.2017.06.003. Epub 2017 Jun 28.
In the last decade, carbapenem-resistant Klebsiella pneumoniae (CR-Kp) has become endemic in several countries, including Italy. In the present study, we assessed the differences in epidemiology, management, and mortality of CR-Kp bloodstream infection (BSI) in the three main adult acute-care hospitals of the metropolitan area of Genoa, Italy. From January 2013 to December 2014, all patients with CR-Kp BSI were identified through the computerized microbiology laboratory databases of the three hospitals. The primary endpoints of the study were incidence and characteristics of CR-Kp BSI in hospitals within the same endemic metropolitan area. Secondary endpoints were characteristics of CR-Kp BSI in hospitals with and without internal infectious diseases consultants (IDCs) and 15-day mortality. During the study period, the incidence of healthcare-associated CR-Kp BSI in the entire study population was 1.35 episodes per 10,000 patient-days, with substantial differences between the three hospitals. Patients admitted to the two hospital with internal IDCs were more likely to receive post-susceptibility test combined therapy including carbapenems (77% vs. 26%, p<0.001), adequate post-susceptibility test therapies (86% vs. 52%, p<0.001), and post-susceptibility therapies prescribed by an infectious diseases specialist (84% vs. 14%, p<0.001). Overall, the crude 15-days mortality was 26%. In the final multivariable model, only septic shock at BSI presentation was unfavorably and independently associated with 15-days mortality (odds ratio [OR] 6.7, 95% confidence intervals [CI] 2.6-17.6, p<0.001), while a protective effect was observed for post-susceptibility test combined therapies including a carbapenem (OR 0.11, 95% CI 0.03-0.43, p=0.002). Mortality of CR-Kp remains high. Differences in the incidence of CR-Kp BSI were detected between acute-care centers within the same endemic metropolitan area. Efforts should be made to improve the collaboration and coordination between centers, to prevent further diffusion of CR-Kp.
在过去的十年中,耐碳青霉烯类肺炎克雷伯菌(CR-Kp)已在包括意大利在内的多个国家流行。在本研究中,我们评估了意大利热那亚大都市区的三家主要成人急性护理医院中,CR-Kp 血流感染(BSI)的流行病学、治疗和死亡率的差异。从 2013 年 1 月至 2014 年 12 月,通过三家医院的计算机化微生物学实验室数据库确定了所有 CR-Kp BSI 患者。该研究的主要终点是同一流行大都市区内医院中 CR-Kp BSI 的发生率和特征。次要终点是具有和不具有内部传染病顾问(IDCs)的医院中 CR-Kp BSI 的特征以及 15 天死亡率。在研究期间,整个研究人群中与医疗保健相关的 CR-Kp BSI 的发生率为每 10000 个患者日 1.35 例,三家医院之间存在很大差异。收治到设有内部 IDC 的两家医院的患者更有可能接受包括碳青霉烯类药物在内的药敏试验后联合治疗(77% vs. 26%,p<0.001)、药敏试验后适当治疗(86% vs. 52%,p<0.001)和传染病专家开出的药敏试验后治疗(84% vs. 14%,p<0.001)。总体而言,未调整的 15 天死亡率为 26%。在最终的多变量模型中,BSI 时仅败血症休克与 15 天死亡率呈不利且独立相关(优势比 [OR] 6.7,95%置信区间 [CI] 2.6-17.6,p<0.001),而药敏试验后联合治疗(包括碳青霉烯类药物)具有保护作用(OR 0.11,95% CI 0.03-0.43,p=0.002)。CR-Kp 的死亡率仍然很高。在同一流行大都市区内的急性护理中心之间检测到 CR-Kp BSI 的发生率存在差异。应努力加强中心之间的协作和协调,以防止 CR-Kp 的进一步扩散。